---
document_datetime: 2023-09-21 18:24:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/emend-epar-procedural-steps-taken-authorisation_en.pdf
document_name: emend-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3901129
conversion_datetime: 2025-12-19 11:30:07.468796
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Merck Sharp &amp; Dohme Ltd. submitted on 30 October 2002 an application for Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for EMEND, through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  25  July  2002,  this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP were:

Rapporteur: Dr Per Nilsson

## Scientific Advice:

The applicant did not seek scientific advice from the CPMP.

## Licensing status:

The product was authorised in the USA on 26 March 2003.

## 2. Steps taken for the assessment of the product

- The procedure started on 18 November 2002.
- The Rapporteur's first Assessment Report was circulated to all CPMP  members  on 28 January 2003 (Annex 1). The Co-Rapporteur's first Assessment Report was circulated to all CPMP members on 3 February 2003 (Annex 2).
- During  the  meeting  on  18-19  March  2003  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 19 March 2003 (Annex 3).
- The  Applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 14 April 2003.
- The  Rapporteur  and Co-Rapporteur  circulated the response Assessment  Report  on  the Applicant's  responses  to  the  List  of  Questions  to  all  CPMP  members  on  26  May  2003 (Annex 4).
- During the meeting on 24-26 June 2003, the CPMP adopted a list of outstanding issues sent to the Applicant on 26 June 2003 (Annex 5).
- The company submitted the responses to the CPMP consolidated list of outstanding issues on 4 July 2003.
- The  Rapporteur  and  Co-Rapporteur  circulated  the  Assessment  Report  on  the  Applicant's responses to the List of Outstanding Issues to all CPMP members on 15 July 2003 (Annex 6).
- During the meeting on 22-24 July 2003, outstanding issues were addressed by the Applicant who gave oral explanations before the CPMP on 23 July 2003.
- During the meeting on 22-24 July 2003 the CPMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to EMEND on 24 July 2003.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 12 November 2003.

Co-Rapporteur: Dr Barbara van Zwieten-Boot